ASCO
Refine search
Biotechnology
US pharma major AbbVie has announced longer-term follow-up results from Phase III studies of Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). 7 June 2016
Pharmaceutical
The vice president of the United States Joe Biden has called for greater collaboration across the oncology treatment community in the fight against cancer. 7 June 2016
Biotechnology
Germany’s Merck (MRK: DE) and US pharma giant Pfizer (NYSE: PFE) plan to file for accelerated approval of avelumab for the treatment of patients with metastatic merkel cell carcinoma (MCC), it has been revealed. 6 June 2016
Pharmaceutical
CHICAGO: Anglo-Swedish drugmaker AstraZeneca has released 'encouraging' early research data for Tagrisso (osimertinib) in patients with leptomeningeal (LM) disease at the American Society of Clinical Oncology (ASCO) annual meeting. 6 June 2016
Biotechnology
US pharma major Bristol-Myers Squibb has presented new data on Opdivo (nivolumab) in fighting renal cell carcinoma and on its use with Yervoy (ipilimumab) in advanced melanoma at the 2016 American Society of Clinical Oncology (ASCO) Meeting. 6 June 2016
Biotechnology
Swiss pharma giant Roche has presented Phase II data showing that Tecentriq (atezolizumab) shrank tumours in people with previously untreated advanced bladder cancer. 6 June 2016
Biotechnology
BioNTech, a privately-held German biotech, has been credited with finding the first example worldwide of a clinically relevant and systemic mRNA cancer immunotherapy. 6 June 2016
Pharmaceutical
One of the largest Phase III trials ever conducted in pancreatic cancer has shown that adding the oral drug capecitabine chemotherapy to gemcitabine prolongs survival without increased toxicity. 6 June 2016
Biotechnology
A Phase III trial of Johnson and Johnson (NYSE: JNJ) subsidiary Janssen’s Darzalex (daratumumab) in combination with Velcade (bortezomib) and dexamethasone (Dvd) in relapsed or refractory multiple myeloma patients has shown a 61% reduction in the risk of disease progression or death. 5 June 2016
Pharmaceutical
Swiss pharma giant Novartis has presented the first results from the Tasigna (nilotinib) treatment-free remission (TFR) clinical trial program at the 52nd American Society of Clinical Oncology (ASCO) annual meeting being held in Chicago. 5 June 2016
Pharmaceutical
A precision medicine approach using a patient’s individual tumor biomarkers to determine the best treatment leads to significantly better outcomes, according to data being presented at this year’s American Society of Clinical Oncology (ASCO) meeting. 4 June 2016
Pharmaceutical
German cancer specialist CellAct Pharma has presented positive new data on CAP7.1 for the treatment of biliary tract cancers at the Annual Meeting of the American Society for Clinical Oncology (ASCO). 3 June 2016
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim has launched a trial to further investigate olmutinib (BI 1482694) as a treatment for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). 3 June 2016
Biotechnology
Nektar Therapeutics has entered into an agreement with the European subsidiary of Japanese drug major Daiichi Sankyo for Nektar's investigational drug therapy, Onzeald (etirinotecan pegol, NKTR-102). 1 June 2016
Biotechnology
Eliot Forster, who became chief executive of Immunocore in January 2015, speaks to The Pharma Letter’s Katie Osborne on why he is so excited about ImmTACs and how the company is working around the clock to get its lead product – IMCgp100 - to a group of patients with no other treatment options. 27 May 2016
Pharmaceutical
Top executives from pharma and biotech companies across the globe are gearing up for one of the industry’s most prestigious annual events. The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) will bring together some thirty thousand professionals from around the world to discuss the latest research and advances in cancer care. 23 May 2016
Pharmaceutical
Patients with metastatic colorectal cancer are more likely to survive if their tumor originates on the left-side of the colon versus the right, a study has revealed. 19 May 2016
Pharmaceutical
Stem cell transplant should remain the preferred treatment for patients with multiple myeloma aged 65 and under, according to a new study. 18 May 2016
Biotechnology
Merck & Co’s Keytruda improves long-term survival rates in newly diagnosed and previously treated patients with advanced melanoma and might even offer a complete cure, according to the results of an early-stage study. 18 May 2016
Biotechnology
Taiwanese biotech PharmaEssentia is preparing to seek an expanded US label for its long-acting interferon Besremi (ropeginterferon alfa-2b) following new late-stage data that show the therapy outperforms anagrelide in treating essential thrombocythaemia (ET) after hydroxyurea failure. 3 June 2025
Pharmaceutical
Detailed results from the Phase III OASIS-4 study have found that Bayer’s elinzanetant showed a statistically significant reduction in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flushes) from baseline to week four and 12 compared to placebo, in women taking endocrine therapy to prevent hormone receptor (HR+) breast cancer. 2 June 2025
Pharmaceutical
Positive results from the SERENA-6 Phase III trial have shown that AstraZeneca’s camizestrant alongside a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) led to a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS). 2 June 2025
Biotechnology
The Alliance for Clinical Trials in Oncology has announced results from ATOMIC, a Phase III trial evaluating standard chemotherapy alone or combined with Roche’s Tecentriq (atezolizumab) in patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). 2 June 2025
Biotechnology
With ASCO 2025 drawing toward its close in Chicago, Amsterdam-based biotech Avidicure is entering the spotlight with its first public data on a new class of cancer immunotherapies. The company’s lead program, AVC-S-101, is designed to target TROP2 in non-small cell lung cancer (NSCLC) and other solid tumors. 2 June 2025
Biotechnology
US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 inhibitor Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. 2 June 2025
Biotechnology
AstraZeneca has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its immunotherapy Imfinzi (durvalumab) to significantly delay disease progression in patients with early-stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers. 2 June 2025
Pharmaceutical
Arcus Biosciences is setting the stage for a high-stakes Phase III showdown in kidney cancer, after early results showed that nearly half of patients treated with its experimental therapy had a confirmed response. 2 June 2025
Pharmaceutical
US drugmaker Protagonist Therapeutics and Japan’s Takeda Pharma announced detailed results from the Phase III, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. 2 June 2025
Pharmaceutical
Arvinas and Pfizer today announced detailed results from the Phase III VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (MBC) whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. 2 June 2025
Pharmaceutical
US pharma giant Pfizer on Saturday announced statistically-significant and clinically-meaningful survival results from the Phase III BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. 2 June 2025
Biotechnology
Daiichi Sankyo and AstraZeneca have released detailed Phase III results that could help position their HER2-targeting drug Enhertu (trastuzumab deruxtecan) as the second-line standard of care for advanced gastric cancer. 2 June 2025
Biotechnology
In the run up to the 2025 annual ASCO meeting, IMUNON (Nasdaq: IMNN) is moving into a Phase III trial with its lead candidate IMNN-001. We interviewed president and chief executive Stacy Lindborg on the long path to this moment—and what may lie ahead in the evolving ovarian cancer treatment landscape. 28 May 2025
Pharmaceutical
Germany’s Merck KGaA today announced the presentation of detailed positive results from Part 1 of the global Phase III MANEUVER trial evaluating pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics, in the treatment of patients with tenosynovial giant cell tumor (TGCT). 28 May 2025
Biotechnology
French biotech ImCheck Therapeutics is preparing to showcase encouraging interim results for its investigational monoclonal antibody ICT01 at the 2025 ASCO Annual Meeting, highlighting the compound’s potential to improve outcomes in acute myeloid leukemia (AML) patients not eligible for intensive chemotherapy. 27 May 2025
Pharmaceutical
Verastem Oncology has unveiled updated early-stage data from its RAMP 205 trial in metastatic pancreatic cancer, bolstering its efforts to broaden use of its dual-drug regimen, Avmapki Fakzynja Co-Pack, beyond its recently approved indication in a rare form of ovarian cancer. 23 May 2025
Pharmaceutical
Japanese drugmaker Astellas and US pharma giant Pfizer have announced longer-term follow-up results from an open-label extension of the Phase III ARCHES study. 23 May 2025
Biotechnology
Among the companies displaying the strength of Chinese research in oncology at the 2025 ASCO Annual Meeting will be Hutchmed. 23 May 2025
Biotechnology
Swiss pharma major Roche has reported updated results from its Phase III STARGLO trial, showing that a fixed-duration regimen of Columvi (glofitamab) combined with gemcitabine and oxaliplatin (GemOx) continues to deliver a notable survival benefit for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). 23 May 2025
Pharmaceutical
The oncology community’s biggest gathering returns to Chicago from May 30 to June 3, and all signs suggest the 2025 ASCO Annual Meeting will be a watershed moment. 23 May 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze